Linda Thunberg

Linda Thunberg

Auto-generated profile, based on publicly available information

Linda Thunberg

Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
ASAnna Said Stålsmeden
Anna Said Stålsmeden
APAndrew J. Paterson
Andrew J. Paterson
ISImola Szigyarto
Imola Szigyarto
LTLinda Thunberg
Linda Thunberg
JJJohan R. Johansson
Johan R. Johansson
NKNina Kann
Nina Kann
1,4- and 1,5-Disubstituted triazole amino acid monomers have gained increasing interest among peptidic foldamers, as they are easily prepared via Cu- and Ru-catalyzed click reactions, with the potential for side chain variation. While the latter is key to their applicability, the synthesis and structural properties of the chiral mono- or disubstituted triazole amino acids have only been partially addressed. We here present the synthesis of all eight possible chiral derivatives of a triazole monomer prepared via a ruthenium-catalyzed azide alkyne cycloaddition (RuAAC). To evaluate the conformational properties of the individual building units, a systematic quantum chemical study was performed on all monomers, indicating their capacity to form several low energy conformers. This feature may be used to effect structural diversity when the monomers are inserted into various peptide sequences. We envisage that these results will facilitate new applications for these artificial oligomeric compounds in diverse areas, ranging from pharmaceutics to biotechnology.

18 February 2025 in Journal of Chromatography A
Verified
Journal Article
Open access
MEMartin Enmark
Martin Enmark
CUCecilia Unoson
Cecilia Unoson
MLMarek Leśko
Marek Leśko
OSOlof Stålberg
Olof Stålberg
KSKathrin Stavenhagen
Kathrin Stavenhagen
TFTorgny Fornstedt
Torgny Fornstedt

1 August 2020 in Journal of Chromatography A
Verified
Journal Article
Closed access
LTLinda Thunberg
Linda Thunberg
ACAnna-Carin C. Carlsson
Anna-Carin C. Carlsson
AJAnna C. Jonson
Anna C. Jonson
SPSubhash Pithani
Subhash Pithani
CACarl-Johan Aurell
Carl-Johan Aurell
HLHanna Leek
Hanna Leek

21 July 2024 in Journal of Chromatography A
Verified
Journal Article
Closed access
JSJörgen Samuelsson
Jörgen Samuelsson
MLMarek Leśko
Marek Leśko
LTLinda Thunberg
Linda Thunberg
AWAnnika Langborg Weinmann
Annika Langborg Weinmann
FLFredrik Limé
Fredrik Limé
TFTorgny Fornstedt
Torgny Fornstedt

22 November 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
JCJonathan Currie
Jonathan Currie
JDJacob. R Dahlberg
Jacob. R Dahlberg
ELEster Lundberg
Ester Lundberg
LTLinda Thunberg
Linda Thunberg
JEJonas Eriksson
Jonas Eriksson
EÖEivor Örnskov
Eivor Örnskov
Modified messenger RNA (mRNA) represents a rapidly emerging class of therapeutic drug product. Development of robust stability indicating methods for control of product quality are therefore critical to support successful pharmaceutical development. This paper presents an ion-pair reversed-phase liquid chromatography (IP- RPLC) method to characterise modified mRNA exposed to a wide set of stress-inducing conditions, relevant for pharmaceutical development of an mRNA drug product. The optimised method could be used for separation and analysis of large RNA, sized up to 1000 nucleotides. Column temperature, mobile phase flow rate and ion-pair selection were each studied and optimised. Baseline separations of the model RNA ladder sample were achieved using all examined ion-pairing agents. We established that the optimised method, using 100 mM Triethylamine, enabled the highest resolution separation for the largest fragments in the RNA ladder (750/1000 nucleotides), in addition to the highest overall resolution for the selected modified mRNA compound (eGFP mRNA, 996 nucleotides). The stability indicating power of the method was demonstrated by analysing the modified eGFP mRNA, upon direct exposure to heat, hydrolytic conditions and treatment with ribonucleases. Our results showed that the formed degradation products, which appeared as shorter RNA fragments in front of the main peak, could be well monitored, using the optimised method, and the relative stability of the mRNA under the various stressed conditions could be assessed

17 November 2025 in Bioanalysis
Verified
Journal Article
Closed access
MJManasses Jora
Manasses Jora
CMChristian Manz
Christian Manz
LTLinda Thunberg
Linda Thunberg
MHMikko Hölttä
Mikko Hölttä
TLTomas Leek
Tomas Leek
WCWerngard Czechtizky
Werngard Czechtizky